Clinical Trials on Central Nervous System Infectious Disorder

Total 237322 results

University of Cape Town

Completed

Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM (LASER-TBM)

HIV-1-infection | Tuberculosis Meningitis

South Africa
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh

Completed

Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose

Encephalitis, Japanese
Martin-Luther-Universität Halle-Wittenberg

Completed

Reducing Visitors- and Personnel-associated Infection Risk on Perinatal Care Station

Hygiene

Germany
PATH

Completed

Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine

Japanese Encephalitis

Sri Lanka
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age (JECEVAX-2B)

Japanese Encephalitis

Vietnam
Boryung Pharmaceutical Co., Ltd

Completed

Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (BR-JELITE)

Japanese Encephalitis

Korea, Republic of
Jiangsu Province Centers for Disease Control and...
Shandong Hengye Biotech Co., Ltd.

Completed

A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants

Encephalitis

China
Valneva Austria GmbH

Completed

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

Japanese Encephalitis

Philippines
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Valneva Austria GmbH

Completed

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Japanese Encephalitis
Valneva Austria GmbH

Completed

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Sanofi

Completed

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Japanese Encephalitis

Australia, United States
Sanofi

Completed

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Japanese Encephalitis | Encephalitis

United States, Australia
Sanofi

Completed

Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine

Japanese Encephalitis

Australia
Sanofi
PRA Health Sciences

Completed

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX

Japanese Encephalitis

United States
Helsinki University Central Hospital
Karolinska Institutet

Completed

Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis

Japanese Encephalitis
Novartis
Novartis Vaccines

Completed

Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years

Encephalitis, Tick-Borne

Germany
Novartis
Novartis Vaccines

Completed

Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

Encephalitis, Tick-Borne

Germany
Indian Council of Medical Research

Unknown

Treatment of Japanese Encephalitis

Japanese Encephalitis

India
Aga Khan University
National Institute of Child Health, Karachi, Pakistan

Not yet recruiting

Role of Ketogenic Diet in SSPE

SSPE
Pfizer

Completed

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Encephalitis, Tick-Borne

Poland
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam (JECEVAX-3)

Japanese Encephalitis

Vietnam
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Safety and Immunogenicity of JECEVAX in Young Children

Japanese Encephalitis

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Study of IMOJEV® in Thailand

Japanese Encephalitis

Thailand
Valneva Austria GmbH

Completed

Safety Surveillance After Immunization With IXIARO

Japanese Encephalitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

Japanese Encephalitis | Encephalitis

Thailand
Khon Kaen University

Unknown

Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children

Japanese Encephalitis

Thailand
University of Liverpool
B.P. Koirala Institute of Health Sciences; Kanti Children's Hospital

Completed

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

Japanese Encephalitis

Nepal
Valneva Austria GmbH

Withdrawn

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Japanese Encephalitis

United Kingdom
Novartis
Novartis Vaccines

Completed

Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children

Encephalitis, Tick-Borne

Germany
University of Edinburgh
NHS Lothian; Department of Health, United Kingdom

Unknown

Enhanced CJD Surveillance in the Older Population

Dementia | Prion Disease

United Kingdom
Johns Hopkins University

Completed

Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis

Epilepsy | Cysticercosis
Turku University Hospital

Active, not recruiting

Effects of Morbid Obesity and Bariatric Surgery on Brain Inflammation, and Activation of Central Reward System (BARIBRAIN)

Morbid Obesity

Finland
University Hospital, Grenoble
University of Liverpool

Unknown

Dexamethasone in Herpes Simplex Virus Encephalitis (DexEnceph)

HSV Encephalitis

France
Michael Iv

Completed

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

Brain Injury | Brain Cancer | Brain Tumors | Primary Brain Neoplasm | Ischemic Cerebrovascular Accident | Central Nervous System Degenerative Disorder | Central Nervous System Infectious Disorder | Central Nervous System Vascular Malformation | Hemorrhagic Cerebrovascular Accident

United States
Sohag University

Completed

Helicobacter Pylori Eradication Therapy for Epileptic Children

Epilepsy, Generalized | Helicobacter Pylori Infection

Egypt
University of Liverpool

Completed

Flavivirus Cross-priming Potential of IMOJEV (FlaviPrime)

Japanese Encephalitis

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

Japanese Encephalitis

Vietnam
PATH
Mahidol University; Ministry of Health of Sri Lanka; Quintiles Singapore

Completed

Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age (JEV03)

Japanese Encephalitis

Sri Lanka
PATH

Completed

Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine

Japanese Encephalitis

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers

Japanese Encephalitis | Encephalitis

Thailand, Philippines
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Chulalongkorn University
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Japanese Encephalitis
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Clinical Trials on Central Nervous System Infectious Disorder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations